WEBULL
WebtradeDownload

Why Gossamer Bio (GOSS) Is Up 42.9% After FDA Clears Path For Seralutinib NDA Submission

Simply Wall St · 4d ago
  • Gossamer Bio recently reported that, following a Pre-NDA Type B meeting with the FDA, it is preparing a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, while also reacquiring worldwide rights to the drug and disclosing approximately US$57,000,000 in cash, cash equivalents and marketable securities as of June 30, 2026.
  • An interesting angle is that the FDA flagged the strength of PROSERA’s results as review issues rather than filing issues, allowing Gossamer to press ahead with an application built on a single Phase 3 trial plus confirmatory evidence.
  • We’ll now explore how the planned seralutinib NDA submission and regained global rights could reshape Gossamer Bio’s existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Gossamer Bio Investment Narrative Recap

To own Gossamer Bio today, you need to believe seralutinib can move from a single pivotal trial into an approved PAH therapy before the balance sheet tightens further. The latest FDA feedback supports a September 2026 NDA as the key near term catalyst, while the biggest immediate risk is whether the company’s roughly US$57,000,000 in cash and securities is sufficient to sustain operations through regulatory review.

Among the recent updates, the reacquisition of worldwide rights to seralutinib from Chiesi stands out. It ties directly into the NDA plan by consolidating all future economics, both upside and downside, with Gossamer. That increases exposure to any regulatory or commercial outcome, so the timing and outcome of the planned US PAH filing now matter even more for how investors think about later ex US indications and any future partnering discussions.

Yet, against this backdrop of opportunity, the combination of limited cash runway and ongoing losses is a risk investors should be aware of...

Read the full narrative on Gossamer Bio (it's free!)

Gossamer Bio's narrative projects $159.3 million revenue and $11.9 million earnings by 2029. This requires 42.1% yearly revenue growth and about a $192 million earnings increase from -$180.4 million today.

Uncover how Gossamer Bio's forecasts yield a $3.86 fair value, a 1766% upside to its current price.

Exploring Other Perspectives

GOSS 1-Year Stock Price Chart
GOSS 1-Year Stock Price Chart

Some of the most optimistic analysts were once modeling revenue near US$380,000,000 and earnings around US$290,000,000 by 2029, but if you worry that rising competition in PAH could cap seralutinib’s eventual market share, this latest FDA and rights update may prompt you to revisit how much of that upside still feels realistic and what a more cautious path might look like.

Explore 9 other fair value estimates on Gossamer Bio - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.